AAP: Starpharma licenses VivaGel BV in Aust, NZ

Mar 9th, 2016

"Starpharma is letting Aspen Pharmacare Australia market and distribute its Vivagel BV treatment in Australia and New Zealand for an undisclosed sum. Aspen will market and distribute the treatment for bacterial vaginosis, that's due to be launched in 2016, to clinicians and pharmacies. In return, Starpharma will receive royalties on net sales.

Starpharma still holds the commercialisation rights in the rest of the world."

Go to the article (external link)

Read More

Starpharma licences VivaGel® BV to Aspen for ANZ

Mar 4th, 2016

Starpharma today announced the signing of a License and Supply Agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel® BV in Australia and New Zealand (ANZ).

Read More

Interim Report and Half-Yearly Financial Results

Feb 17th, 2016

Starpharma  today released its interim report and financial results for the half-year ended 31 December 2015.

Financial Summary

  • Reported loss of $10.0M (Dec 2014: $8.5M)
  • Revenue of $3.7M (Dec 2014: $0.7M)
  • R&D tax incentives of $1.8M reported in the half-year (Dec 2014: $1.6M)
  • Cash position at 31 December 2015 of $54.7M (June 2015: $30.8M)
  • Cash inflows of $7.2M from partners and grants, includes US$2.0M from AstraZeneca and $3.4M R&D tax incentive refund
  • Proceeds from completion of $32.0M equity placement
Read More

Targeted DEP™ shows sustained superior performance

Feb 2nd, 2016

Starpharma today announced the final results of the preclinical study of its HER2-targeted DEP™ conjugate, which achieved complete tumour regression at the last study time point of 120 days post dosing.

Read More

Appendix 4C - Quarterly Cashflow Report

Jan 28th, 2016

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2015.

Read More

Starpharma raises $1.9M under Share Purchase Plan

Jan 20th, 2016

Starpharma announced it has completed its Share Purchase Plan (SPP) having raised approximately $1.9 million. Combining the SPP with the recent institutional placement which raised $32 million (before costs); the Company has successfully raised a total of approximately $34 million at $0.73 per share.

Read More

The Age: Starpharma set for condom sales in China

Dec 17th, 2015

"Starpharma has signed a memorandum of understanding with a Chinese company to make and sell its VivaGel-coated condom in China...The Chinese company is a major supplier of condoms to the Chinese government's Birth Control Department and Disease Prevention Department. The so-called government market in China requires about three billion condoms each year for birth control and disease prevention."

Go to the article (external link)

Read More

Share Purchase Plan Offer Documents

Dec 16th, 2015

Starpharma is pleased to attach documentation regarding its Share Purchase Plan (SPP).

Read More

Starpharma signs MOU for VivaGel condom in China

Dec 16th, 2015

Starpharma announced today that it has signed a Memorandum of Understanding (MOU) with a Chinese company who is a major provider of condoms to the Chinese government.  The MOU outlines the key commercial and other terms for Starpharma’s partner to manufacture and sell a VivaGel® coated condom to the Government segment of the Chinese market.

Read More

Starpharma completes A$32 million placement - SPP to follow

Dec 9th, 2015

Starpharma is pleased to announce it has raised A$32 million via a placement to domestic and international institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will also have the opportunity to participate, at the same price, through a Share Purchase Plan (SPP) which will raise up to a further A$3 million.

Read More

Second DEP™ candidate selected by AstraZeneca

Dec 2nd, 2015

Starpharma today announced that AstraZeneca has selected a second DEP™ candidate and Starpharma will now commence a new DEP™ project incorporating the second proprietary AstraZeneca oncology molecule.

Read More

AGM - Chair address and CEO presentation

Nov 19th, 2015

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 2.00pm today.

Download: AGM - Chair address and CEO presentation (pdf file, 1MB)

Read More